Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Aug 14;21(1):920.
doi: 10.1186/s12885-021-08656-0.

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Christine Stürken  1 , Volker Möbus  2 , Karin Milde-Langosch  3 , Sabine Schmatloch  4 , Peter A Fasching  5 , Josef Rüschoff  4 , Elmar Stickeler  6 , Rolf-Peter Henke  7 , Carsten Denkert  8 , Lars Hanker  9   10 , Christian Schem  11 , Valentina Vladimirova  12 , Thomas Karn  10 , Valentina Nekljudova  12 , Claus-Henning Köhne  7 , Frederik Marmé  13 , Udo Schumacher  1 , Sibylle Loibl  12 , Volkmar Müller  14
Affiliations
Multicenter Study

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Christine Stürken et al. BMC Cancer. .

Erratum in

  • Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
    Stürken C, Möbus V, Milde-Langosch K, Schmatloch S, Fasching PA, Rüschoff J, Stickeler E, Henke RP, Denkert C, Hanker L, Schem C, Vladimirova V, Karn T, Nekljudova V, Köhne CH, Marmé F, Schumacher U, Loibl S, Müller V. Stürken C, et al. BMC Cancer. 2021 Sep 15;21(1):1024. doi: 10.1186/s12885-021-08754-z. BMC Cancer. 2021. PMID: 34526003 Free PMC article. No abstract available.

Abstract

Background: Breast cancer (BC) is the most frequent female cancer and preferentially metastasizes to bone. The transcription factor TGFB-induced factor homeobox 1 (TGIF) is involved in bone metabolism. However, it is not yet known whether TGIF is associated with BC bone metastasis or patient outcome and thus of potential interest.

Methods: TGIF expression was analyzed by immunohistochemistry in 1197 formalin-fixed, paraffin-embedded tissue samples from BC patients treated in the GAIN (German Adjuvant Intergroup Node-Positive) study with two adjuvant dose-dense schedules of chemotherapy with or without bisphosphonate ibandronate. TGIF expression was categorized into negative/low and moderate/strong staining. Endpoints were disease-free survival (DFS), overall survival (OS) and time to primary bone metastasis as first site of relapse (TTPBM).

Results: We found associations of higher TGIF protein expression with smaller tumor size (p = 0.015), well differentiated phenotype (p < 0.001) and estrogen receptor (ER)-positive BC (p < 0.001). Patients with higher TGIF expression levels showed a significantly longer disease-free (DFS: HR 0.75 [95%CI 0.59-0.95], log-rank p = 0.019) and overall survival (OS: HR 0.69 [95%CI 0.50-0.94], log-rank p = 0.019), but no association with TTPBM (HR 0.77 [95%CI 0.51-1.16]; p = 0.213). Univariate analysis in molecular subgroups emphasized that elevated TGIF expression was prognostic for both DFS and OS in ER-positive BC patients (DFS: HR 0.68 [95%CI 0.51-0.91]; log-rank p = 0.009, interaction p = 0.130; OS: HR 0.60 [95%CI 0.41-0.88], log-rank p = 0.008, interaction p = 0.107) and in the HER2-negative subgroup (DFS:HR 0.67 [95%CI 0.50-0.88], log-rank p = 0.004, interaction p = 0.034; OS: HR 0.57 [95%CI 0.40-0.81], log-rank p = 0.002, interaction p = 0.015).

Conclusions: Our results suggest that moderate to high TGIF expression is a common feature of breast cancer cells and that this is not associated with bone metastases as first site of relapse. However, a reduced expression is linked to tumor progression, especially in HER2-negative breast cancer.

Trial registration: This clinical trial has been registered with ClinicalTrials.gov ; registration number: NCT00196872 .

Keywords: Bone metastases; Breast cancer; TGFB-induced factor homeobox 1; TGIF.

PubMed Disclaimer

Conflict of interest statement

V.M: Dr. Möbus received speaker honoraria from Amgen, Astra Zeneca, Celgene, Roche, Teva, and consultancy honoraria from Roche, Amgen, Tesaro and Myelo Therapeutics GmbH.

V.M: Dr. Müller received speaker honoraria from Amgen, Astra Zeneca, Celgene, Daiichi-Sankyo, Eisai, Pfizer, Novartis, Roche, Teva, and consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, Novartis, MSD, Daiichi-Sankyo and Eisai, Lilly, Tesaro and Nektar. Research support from Novartis, Roche, Seattle Genetics, Genentech.

PAF: Dr. Fasching reports grants from Novartis, grants from Biontech, personal fees from Novartis, personal fees from Roche, personal fees from Pfizer, personal fees from Celgene, personal fees from Daiichi-Sankyo, personal fees from Astra Zeneca, personal fees from Macrogenics, personal fees from Eisai, personal fees from Merck Sharp & Dohme, grants from Cepheid, personal fees from Lilly, during the conduct of the study.

ES: Dr. Stickeler reports personal fees from Roche Pharma, personal fees from Novartis, personal fees from Pfizer, personal fees from Tesaro, personal fees from Astra Zeneca, outside the submitted work.

CD: Dr. Denkert received honoraria from Novartis and Roche; Research funding from Myriad Genetics, reports consulting or advisory role for MSD Oncology and Daiichi Sankyo and stock and other ownership interest with Sividon Diagnostics (now Myriad and travel expenses from Roche. In addition, Dr. Denkert has patents, royalities and intellectual property with VMscopedigital pathology software: Patent application: EP18209672 - cancer immunotherapy; Patent application EP20150702464 - therapy response; Patent application EP20150702464 - therapy response.

LH: Dr. Hanker received speaker honoraria from Astra Zeneca, Clovis, GSK/Tesaro Novartis, Roche, and consultancy honoraria from Astra Zeneca, Clovis, GSK/Tesaro and Roche.

FM: Dr. Marmé reports personal fees from Roche, personal fees from AstraZeneca, personal fees from Pfizer, personal fees from Tesaro, personal fees from Novartis, personal fees from Amgen, personal fees from PharmaMar, personal fees from GenomicHealth, personal fees from CureVac, personal fees from EISAI, outside the submitted work.

SL: Dr. Loibl reports grants and other from Abbvie, grants and other from Amgen, grants and other from Astra Zeneca, grants and other from Celgene, grants and other from Novartis, grants and other from Pfizer, grants and other from Roche, other from Seattle Genetics, other from PriME/ Medscape, personal fees from Chugai, grants from Teva, grants from Vifor, grants and other from Daiichi-Sankyo, other from Lilly, other from Samsung, other from Eirgenix, other from BMS, other from Puma, other from MSD, grants from Immunomedics, outside the submitted work; In addition, Dr. Loibl has a patent EP14153692.0 pending.

The other authors (CS; KML; SS; JR; RPH; TK; CS; CHK; LH; US; VV; VN) declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of the technical proceeding
Fig. 2
Fig. 2
Representative pictures of TGIF immunostaining; A Tumor with normal epithelium; B negative; C low; D moderate and E strong TGIF expression in breast cancer samples. Scale bar 200 / 50 μm
Fig. 3
Fig. 3
Kaplan-Meier analysis for DFS (A) (HR 0.75 [95%CI 0.59–0.95]; log rank p = 0.019), OS (B) HR 0.69 [95%CI 0.50–0.94]; log rank p = 0.019) and TTPBM (C) (HR 0.77 [95%CI 0.51–1.16]; p = 0.213) according to the overall TGIF immunostaining (moderate/strong vs negative/low). DFS, disease-free survival, OS, overall survival; TTPBM, time to primary bone metastasis
Fig. 4
Fig. 4
Subgroup analysis for DFS and OS according to the TGIF immunostaining (moderate/strong vs negative/low) with regards to treatment arm (iddEPC and ddEC-PwX): A DFS iddEPC treatment (HR 0.70 [95% CI 0.50–0.98]; log-rank p = 0.037). B OS iddEPC treatment (HR 0.69 [95% CI 0.45–1.07]; log-rank p = 0.096). C DFS iddEC-PwX treatment (HR 0.81 [95% CI 0.58–1.14]; log-rank p = 0.229). D OS iddEC-PwX treatment HR 0.69 [95% CI 0.45–1.08]; log-rank p = 0.106
Fig. 5
Fig. 5
Stratified Kaplan-Meier analysis for DFS and OS by estrogen receptor (ER) status, by HER2 status, and by triple-negative status: A DFS in ER-positive BC subgroup (HR 0.68; 95%CI 0.51–0.91; log-rank p = 0.009) B OS in ER-positive BC subgroup (HR 0.60; 95%CI 0.41–0.88; log-rank p = 0.008); C DFS in HER2-negative BC subgroup (HR 0.67; 95%CI 0.50–0.88; log-rank p = 0.004) D OS in HER2-negative BC subgroup (HR 0.57; 95%CI 0.40–0.81; log-rank p = 0.002) E DFS in non-TNBC subgroup (HR 0.76; 95%CI 0.58–1.00; log-rank p = 0.049) F OS in non-TNBC subgroup (HR 0.70; 95%CI 0.48–1.01; log-rank p = 0.056)
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Weigelt B, Peterse JL, van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591–602. doi: 10.1038/nrc1670. - DOI - PubMed
    1. Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150. doi: 10.1016/S0140-6736(16)31891-8. - DOI - PubMed
    1. O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474. - PMC - PubMed
    1. Menshawy A, Mattar O, Abdulkarim A, Kasem S, Nasreldin N, Menshawy E, et al. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2018;26(4):1029–38. 10.1007/s00520-018-4060-1. - PubMed

Publication types

MeSH terms

Associated data